Browse > Article

Affinity Maturation of an Anti-Hepatitis B Virus PreS1 Humanized Antibody by Phage Display  

Yang, Gi-Hyeok (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology)
Yoon, Sun-Ok (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology)
Jang, Myung-Hee (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology)
Hong, Hyo-Jeong (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology)
Publication Information
Journal of Microbiology / v.45, no.6, 2007 , pp. 528-533 More about this Journal
Abstract
In a previous study we generated an anti-Hepatitis B Virus (HBV) preS1 humanized antibody (HzKR127) that showed in vivo HBV-neutralizing activity in chimpanzees. However, the antigen-binding affinity of the humanized antibody may not be sufficient for clinical use and thus affinity maturation is required for better therapeutic efficacy. In this study, phage display technique was employed to increase the affinity of HzKR127. All six amino acid residues (Glu95-Tyr96-Asp97-Glu98-Ala99-Tyr100) in the heavy (H) chain complementary-determining region 3 (HCDR3) of HzKR127 were randomized and phage-displayed single chain Fv (scFv) library was constructed. After three rounds of panning, 12 different clones exhibiting higher antigen-binding activity than the wild type ScFv were selected and their antigen-binding specificity for the preS1 confirmed. Subsequently, five ScFv clones were converted to whole IgG and subjected to affinity determination. The results showed that two clones (B3 and A19) exhibited an approximately 6 fold higher affinities than that of HzKR127. The affinity-matured humanized antibodies may be useful in anti-HBV immunotherapy.
Keywords
humanized antibody; phage display; random mutagenesis; HCDR3; affinity maturation; hepatitis B virus; preS1;
Citations & Related Records

Times Cited By Web Of Science : 5  (Related Records In Web of Science)
Times Cited By SCOPUS : 5
연도 인용수 순위
1 Dreesman, G.R., Y. Sanchez, I. Ionescu-Matiu, J.T. Sparrow, H.R. Six, D.L. Peterson, F.B. Hollinger, and J.L. Melnick. 1982. Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature 295, 158-160   DOI   ScienceOn
2 Itoh, Y., E. Takai, H. Ohnuma, K. Kitayima, F. Tsuda, A. Machida, S. Mishiro, T. Nakamura, Y. Miyakawa, and M. Mayumi. 1986. A synthetic peptide vaccine involving the product of the preS2 region of hepatitis B virus: protective efficacy in chimpanzees. Proc. Natl. Acad. Sci. USA 83, 9174-9178
3 Kim, H.S and H.J. Hong, 1995. Efficient expression, purificaion and characterization of hepatitis B virus perS1 protein from Escherichia coli. Biotechnol. Lett. 17, 871-876   DOI
4 Marks, J.D., H.R. Hoogenboom, T.P. Bonnert, J. McCafferty, A.D. Griffiths, and G. Winter. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581
5 Milich, D.R. 1987. Immunological response to pre-S antigens of the hepatitis B virus. Viral. Immunol. 1, 83-96   DOI
6 Oh, M.S., K.S. Kim, Y.K. Jang, C.Y. Maeng, S.H. Min, M.H. Jang, S.O. Yoon, J.H. Kim, and H.J. Hong. 2003. A new epitope tag from hepatitis B virus preS1 for immunodetection, localization and affinity purification of recombinant proteins. J. Immunol. Meth. 283, 77   DOI   ScienceOn
7 Winter, G., A.D. Griffiths, R.E. Hawkins, and H.R. Hoogenboom. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455   DOI   ScienceOn
8 Burton, D.R., C.F. Barbas, 3rd, M.A. Persson, S. Koenig, R.M. Chanock, and R.A. Lerner. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134
9 Shawler, D.L., R.M. Bartholomew, L.M. Smith, and R.O. Dillman. 1985. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 135, 1530-1535   PUBMED
10 Hong, H.J., C.J. Ryu, H. Hur, S. Kim, H.K. Oh, M.S. Oh, and S.Y. Park. 2004. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 318, 134-138   DOI   ScienceOn
11 Krykbaev, R.A., W.R. Liu, P.D. Jeffrey, and M.N. Margolies. 2001. Phage display-selected sequences of the heavy-chain CDR3 loop of the anti-digoxin antibody 26-10 define a high affinity binding site for position 16-substituted analogs of digoxin. J. Biol. Chem. 276, 8149-8158   DOI   ScienceOn
12 Persing, D.H., H.E. Varmus, and D. Ganem. 1986 Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. Science 234, 1388-1391   DOI
13 Komissarov, A.A., M.T. Marchbank, M.J. Calcutt, T.P. Quinn, and S.L. Deutscher. 1997. Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity- determining region 3 residues in antigen interaction. J. Biol. Chem. 272, 26864-26870   DOI   ScienceOn
14 Bhatnager, P.K., E. Papas, H.E. Blum, D.R. Milich, D. Nitecki, M.J. Kareb, and G.N. Vyas. 1982. Immune response to synthetic peptide analogues of HBsAg specific for the a detertminant. Proc. Natl. Acad. Sci. USA 79, 4723-4727
15 Horton, R.M., H.D. Hunt, S.N. Ho, J.K. Pullen, and L.R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77, 61   DOI   ScienceOn
16 Heermann, K.H., U. Goldmann, W. Schwartz, T. Seyffarth, H. Baumgarten, and W.H. Gerlich. 1984. Large surface proteins of hepatitis B virus containing the pre-s sequence. J. Virol. 52, 396-402   PUBMED
17 Neurath, A.R., B. Seto, and N. Strick. 1989. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 7, 234-236   DOI   ScienceOn
18 Ryu, C.J., D.Y. Cho, P. Gripon, H.S. Kim, C. Guguen-Guillouzo, and H.J. Hong. 2000. An 80-kilodalton protein that binds to the pre-S1 domain of hepatitis B virus. J. Virol. 74, 110-116   DOI
19 Griffiths, A.D., S.C. Williams, O. Hartley, I.M. Tomlinson, P. Waterhouse, W.L. Crosby, R.E. Kontermann, P.T. Jones, N.M. Low, T.J. Allison, T.D. Prospero, H.R. Hoogenboom, A. Nissim, J.P.L. Cox, J.L. Harrison, M. Zaccolo, E. Gherardi, and G. Winter. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245-3260   PUBMED
20 Pontisso, P., M.G. Ruvoletto, W.H. Gerlich, K.H. Heermann, R. Bardini, and A. Alberti. 1989. Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology 173, 522-530   DOI   ScienceOn
21 Xu, J.L. and M.M. Davis. 2000. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Cell 13, 37-45
22 Stibbe, W. and W.H. Gerlich. 1983. Structural relationships between minor and major proteins of hepatitis B surface antigen. J. Virol. 46, 626-628   PUBMED
23 Heermann, K.H., F. Kruse, M. Seifer, and W.H. Gerlich. 1987. Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments. Intervirology 28, 14-25   DOI
24 Neurath, A.R., S.B. Kent, N. Strick, and K. Parker. 1986. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46, 429-436   DOI   ScienceOn
25 Maeng, C.Y., C.J. Ryu, P. Gripon, C. Guguen-Guillouzo, and H.J. Hong. 2000. Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1. Virology 270, 9-16   DOI   ScienceOn